VV119 dose and safety study in healthy adults and adults with schizophrenia
About this title
Read the official source — NCT06504290Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
What will I do during this study?
The study has two parts: healthy adults receive daily oral VV119 or placebo (an inactive comparison treatment) for 14 days; adults with schizophrenia receive dose-escalating VV119 or placebo for up to 28 days.
- Listed locations
- Beijing and 3 more locationsSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 40
- Sponsor
- Vigonvita Life Sciences
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- China
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06504290
- Official title
Show the full official title
A Phase I Clinical Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VV119 Capsules With Multiple Ascending Doses in Chinese Healthy Adult Subjects and Patients With Schizophrenia
Recruitment & locations
Beijing · Xi’an
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Vigonvita Life Sciences.
Does this study involve medication?
Yes. The study involves medication, including VV119 Placebo and VV119.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
